Recent developments in gene transfer: risk and ethics
- 6 January 2005
- Vol. 330 (7482) , 79-82
- https://doi.org/10.1136/bmj.330.7482.79
Abstract
Since the early 1990s, investigators have toiled to establish the transfer of genes to human somatic cells as a valid therapy (fig 1). The potential of gene transfer was highlighted by three trials, involving participants with haemophilia B and two types of severe combined immunodeficiency—X linked and adenosine deaminase deficient.1–3 Yet even the most successful trials of gene transfer have engendered questions about its prospects. In the haemophilia B trial the detection of vector—the agent which carries genes to cells (fig 2)—in participants' semen raised concerns about modifications of the germline.4 The results of the X linked severe combined immunodeficiency trial were offset by unexpected, vector induced leukaemia in two participants.5 Fig 1 Number of gene transfer trials approved worldwide has increased since 1989; 77% have been conducted in the United States and the United Kingdom. Most trials have used virus based vectors (70%), are phase 1 (63%), and involve investigational treatments for cancer (66%). Adapted from Wiley Gene Therapy Clinical Trial Database (http://www.wiley.co.uk/wileychi/genmed/clinical/) Fig 2 In a gene transfer, therapeutic DNA is combined with a vector (often of viral origin). Vectors can be injected into recipient's tissue directly or used to modify cells ex vivo for transplantation to the recipient Several hazards associated with gene transfer have been verified by clinical experience and others are predicted on theoretical grounds. It therefore may be worth considering whether risks shown in studies of human gene transfer present any unusual ethical and social challenges and, if so, what should be done to tackle them. In this article I review several matters relating to human gene transfer—safety features that distinguish traditional drugs from agents used to transfer genes, ethical issues raised by uncertainties about risk and toxicological properties, and studies on safety. I searched for relevant articles in Medline through PubMed …Keywords
This publication has 19 references indexed in Scilit:
- Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative ConditioningScience, 2002
- Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene TherapyNew England Journal of Medicine, 2002
- Viral Vectors Still Pack SurprisesScience, 2001
- Points to Consider for Ethics Committees in Human Gene Therapy TrialsBioethics, 2001
- Starting clinical trials of xenotransplantation—reflections on the ethics of the early phaseJournal of Medical Ethics, 2000
- What Makes Clinical Research Ethical?JAMA, 2000
- Regulatory Issues: Gene Therapy Advisory Committee. Long-Term Monitoring of Patients Participating in Gene Therapy. Health Departments of the United KingdomHuman Gene Therapy, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Defining and Describing Benefit Appropriately in Clinical TrialsJournal of Law, Medicine & Ethics, 2000
- Postmarketing Surveillance and Adverse Drug ReactionsPublished by American Medical Association (AMA) ,1999